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Articles on similar topics can be found in the following collections IE with positive blood cultures This is the most important category, representing about 85% of all episodes of IE. Causative microorganisms are most often streptococci, enterococci, and staphylococci.
IE caused by streptococci and enterococci
Oral streptococci form a mixed group of microorganisms, which includes species such as Streptococcus sanguis, S mitis, S salivarius, and S mutans, to which one usually adds Gemella morbillorum (formerly S morbillorum). Microorganisms of this group are almost always susceptible to penicillin G. Members of the ''S milleri'' or ''S anginosus'' group (S anginosus, S intermedius, and S constellatus) must be distinguished from the former group because they tend to form abscesses and cause haematogenously disseminated infection, which often requires a longer duration of antibiotic treatment. Likewise, nutritionally-variant ''defective'' streptococci, which were recently reclassified into other species (Abiotrophia and Granulicatella), should also be distinguished because they are often tolerant to penicillin (minimal bactericidal concentration (MBC) much higher than the mimimal inhibiting concentration (MIC)). Group D streptococci form the ''Streptococcus bovis/Streptococcus equines'' complex, which includes several commensal species of the human intestinal tract and were until recently grouped under the name of Streptococcus bovis. They are generally quite sensitive to penicillin G, like oral streptococci.
Among enterococci, Enterococcus faecalis, E faecium, and to a lesser extent E durans, are the three species that can cause IE.
Staphylococcal IE
Traditionally, episodes of native valve staphylococcal IE are caused by S aureus, which are most often susceptible to oxacillin, at least when the strains are community-acquired. By contrast, in prosthetic valve IE, staphylococci are more frequently coagulase-negative staphylococci and are often oxacillin-resistant. However, in a recent study of 1779 cases of IE collected prospectively in 16 countries, S aureus was not only the principal cause of IE but also the main cause of prosthetic valve IE. 5 Conversely, coagulase-negative staphylococci can also cause native valve IE. 10 IE with negative blood cultures because of prior antibiotic treatment This is the usual situation in a patient in whom the diagnosis of IE was not considered and who received antibiotics for an unexplained fever before any blood culture was performed; the diagnosis is eventually considered in the face of relapsing febrile episodes following antibiotic discontinuation. Blood cultures may remain negative for many days after antibiotic discontinuation and causative organisms are most often oral streptococci or coagulase-negative staphylococci.
IE with often negative blood cultures
These cases of IE are usually caused by fastidious organisms such as nutritionally-variant streptococci, fastidious Gramnegative bacilli of the HACEK group (Haemophilus parainfluenzae, H aphrophilus, H paraphrophilus, H influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae and K denitrificans), Brucella, and fungi.
IE with always negative blood cultures
These cases are caused by intracellular bacteria such as Coxiella burnetii, Bartonella, Chlamydia, and, as recently demonstrated, Tropheryma whipplei, the bacterium causing Whipple's disease. 11 Altogether, they may account for up to 5% of all cases of IE. The diagnosis of such cases of IE relies on specific samples for cell culture or gene amplification.
ANTIBIOTIC TREATMENT

Theoretical considerations
The vegetation that characterises IE is composed of a mixture of fibrin and platelets, contains a large inoculum of bacteria, and is often enclosed in a layer of exopolysaccharides that hampers antibiotic penetration. Thus antibiotic treatment should be bactericidal, and the bactericidal activity should ideally be obtained rapidly and maintained until cure is obtained. However, cure may be difficult to achieve for several reasons: c pharmacokinetic: the penetration of some antibiotics inside the vegetation may be very heterogeneous, which may explain why some antibiotics cannot eradicate the microorganism in large vegetations; c pharmacodynamic: the concentrations of antibiotics within the vegetation must be sufficiently high and sustained; the absence of post-antibiotic effect of blactams on Gram-positive cocci makes it mandatory to maintain short intervals between doses of antibiotics in order to achieve permanent high serum concentrations, several-fold higher than the MIC of the causative microorganism; furthermore, the high bacterial density and the slow metabolic activity of the bacteria inside the vegetation may result in an in vivo sensitivity lower than that predicted by standard in vitro tests; finally antibiotics active against actively growing bacteria (b-lactams, glycopeptides) have a reduced activity against bacteria whose metabolic activity is reduced.
Practical aspects of antibiotic treatment of IE
The intravenous route for antibiotic administration is the best since it provides maximal bioavailability. Most antibiotics are administered as short infusions (30 minutes). There are some exceptions, however. Penicillin G is usually administered continuously because of the risk of seizures secondary to the high serum concentrations achieved with intermittent infusion. One-to two-hour infusions of vancomycin improve the tolerability of the drug. For antibiotics with timedependent effects (b-lactams), the interval between infusions must be adjusted to take the elimination half-life into account. For antibiotics with concentration-dependent effects (aminoglycosides), twice-or thrice-daily administration is recommended. However, there are experimental and clinical data in favour of once-daily administration of gentamicin or netilmicin in IE caused by penicillin-sensitive streptococci. [12] [13] [14] Both the efficacy and the tolerance of the treatment need to be carefully monitored. In terms of efficacy, apart from the absence of relapse at the end of the treatment, there is no totally reliable clinical or biological criterion. This emphasises the importance of clinical and biological surveillance (disappearance of fever, sterilisation of blood cultures, and normalisation of inflammation markers) during treatment and in the subsequent four weeks (period of maximal risk of relapse of IE). The determination of blood concentrations of antibiotics, especially aminoglycosides, is useful to verify both that the peak concentrations are high enough (efficacy objective) and that the trough concentrations are not excessively high (tolerance objective).
Recommendations for the antibiotic treatment of IE
The most recent recommendations for the antibiotic treatment of IE were issued by the European Society of Cardiology 15 and the American Heart Association. 16 Antibiotic treatment of streptococcal and enterococcal IE
We will only discuss in this section IE caused by oral streptococci, group D streptococci, and enterococci, for which there is a clear consensus in the literature (tables 1 and 2).
Native valve streptococcal endocarditis
In the absence of allergy to penicillin, the treatment of IE caused by highly penicillin-susceptible streptococci (MIC (0.1 mg/l)-most oral and group D streptococci-should combine penicillin G, 10-20 million units per day, with an aminoglycoside (gentamicin, 3 mg/kg/day, or netilmicin, 5-6 mg/kg/day, in one daily dose). The combination is administered for two weeks, provided that all the following conditions for short-course therapy are fulfilled: highly penicillin-susceptible streptococcal strain; native valve endocarditis; no heart failure, aortic insufficiency or conduction abnormalities; no evidence of extracardiac septic complications; vegetation diameter ( 10 mm; clinical response within seven days (temperature returns to normal); and no surgical treatment of endocarditis. In patients with contraindications to aminoglycosides, penicillin alone for four weeks is as effective as the previous regimens. In patients with complicated IE, the combination is administered for two weeks followed by two weeks of penicillin alone. In all these regimens, penicillin G may be conveniently replaced by ceftriaxone (2 g once daily). 13 14 17 For streptococci with reduced susceptibility to penicillin (0.1 , MIC (0.5 mg/l), the same combination of penicillin and aminoglycoside is given, with higher doses of penicillin (30 million units per day in adults). Ampicillin and amoxicillin are alternatives to penicillin, 200 mg/kg/day in six infusions. This regimen should also be given for IE caused by tolerant streptococci. The combination should be given for two weeks and followed by b-lactam monotherapy, with a total duration of treatment of at least four weeks, and up to six weeks in complicated IE.
IE caused by streptococci with MIC . 0.5 mg/l as well as IE due to nutritionally variant streptococci (Abiotrophia and Granulicatella) should be treated in the same way as enterococcal IE.
Native valve enterococcal endocarditis
Enterococci are now classified as an individual genus. E faecalis, E faecium and, to a lesser extent, E durans are most commonly responsible for IE. They are far less sensitive to penicillins than streptococci. MICs to b-lactams are 10-to 100-fold higher for enterococci than for streptococci. This is even more pronounced for E faecium than for E faecalis, with MIC 50 to penicillin of 8 and 1 mg/l and to amoxicillin of 4 and 0.5 mg/l, respectively. In addition, E faecium strains are almost always penicillin-tolerant. b-lactamase producing strains of E faecalis have been described in the United States, but not yet in Europe.
High-level resistance to aminoglycosides is found in about 10% of endocarditis strains of E faecalis. For management of endocarditis, enterococcal isolates must be routinely checked for high-level resistance in order to avoid the use of aminoglycosides when no synergy with either b-lactams or glycopeptides can be expected. In addition, netilmicin should not be used in E faecium IE because this species possesses a constitutive AAC6' enzyme that inactivates netilmicin.
Glycopeptide-resistant enterococci were first described in the late 1980s. Most often these strains exhibit high-level resistance to both vancomycin (MIC .64 mg/l) and teicoplanin (MIC .16 mg/l). This resistance profile (van-A phenotype) is plasmid-mediated-that is, potentially transferable from one strain to another. Occasionally (mostly in Europe) teicoplanin sensitivity is preserved despite presence of high-level resistance to vancomycin (van-B phenotype).
Optimal antibiotic prescribing for enterococcal IE requires that MICs of penicillin, amoxicillin, aminoglycosides, and glycopeptides be determined. When the strain exhibits only low-level resistance to aminoglycoside, recommended therapy is a combination of high-dose b-lactam (30-40 million units/ day penicillin or 200 mg/kg/day amoxicillin) plus gentamicin for 4-6 weeks. The aminoglycoside component should be administered in two or three equally divided doses; this recommendation is based on results of experimental studies. 18 In the case of high-level resistance to gentamicin, crossresistance may be expected with all other aminoglycosides, except sometimes streptomycin. If the strain shows low-level resistance to streptomycin, the latter can be used in combination with high doses of a cell-wall active agent, either a b-lactam or a glycopeptide. If the strain shows highlevel resistance to streptomycin as well, the best treatment option is monotherapy with amoxicillin or a glycopeptide given at high dose for at least eight weeks. Even with such prolonged treatment, antibiotic therapy often fails, and surgery is likely to be required.
Glycopeptide-resistant enterococci are often multidrug resistant, also exhibiting high MICs to b-lactams and high levels of resistance to aminoglycosides. In vitro studies showed that combinations of cell-wall active antibiotics may be synergistic in such strains without an added aminoglycoside. This was demonstrated for combinations such as teicoplanin-imipenem, 19 ampicillin-ceftriaxone, 20 21 and ampicillin-imipenem 22 on E faecalis strains. Ampicillin (12 g daily)-ceftriaxone (2 g daily) and ampicillin (12 g daily)-imipenem-ceftriaxone (2 g daily) are now recommended for the treatment of multidrug resistant E faecalis IE. 16 Combinations of cell-wall active agents are, however, insufficient for the treatment of E faecium IE. Newer agents such as quinupristin-dalfopristin and linezolid appear to be preferable options in this setting. Quinupristin-dalfopristin (Q/D) (Synercid) is a new parenteral streptogramin combination which is potent against most Gram-positive pathogens, including multidrug resistant E faecium, with the notable exception of E faecalis. In multidrug resistant E faecium endocarditis, Q/D was effective in an animal model and in anecdotal case reports. 23 Linezolid is the first licensed representative of the oxazolidinones, a new class of antibiotics that acts by inhibiting protein synthesis. Linezolid has significant activity against mutiresistant Gram-positive pathogens, including vancomycin-resistant enterococci. Only a few studies have evaluated this compound in the treatment of IE. Further studies are needed to confirm the potential value of these two new drugs as well as newer glycopeptides (dalbavancin, telavancin) and lipopeptides (daptomycin) for the treatment of enterococcal endocarditis.
Prosthetic valve endocarditis caused by streptococci and enterococci
The same regimens as for native valve IE are recommended. The minimal duration of treatment is four weeks for highly susceptible streptococci and six weeks for enterococci, with at least two weeks and four weeks of b-lactam-aminoglycoside combination, respectively. If the prosthetic valve is replaced during the course of antibiotic treatment, the duration of antibiotic treatment should be 4-6 weeks if valve culture is found to be positive. Otherwise, the total duration of treatment should not be prolonged. 24 
Streptococcal and enterococcal endocarditis in patients allergic to penicillin
In patients allergic to penicillin, vancomycin is the best alternative. Teicoplanin, another glycopeptide, can also be used (loading dose 6 mg/kg every 12 hours for 48-72 hours, followed by a once-daily dose of 6-10 mg/kg.
Antibiotic treatment of staphylococcal IE (table 3)
Native valve staphylococcal endocarditis
In the absence of allergy to penicillin, if the staphylococcal strain is oxacillin-susceptible, oxacillin or cloxacillin (150 mg/kg/day in six intravenous infusions, maximal daily dose 6-8 g) should be used in combination with an aminoglycoside (gentamicin or netilmicin) for the first 3-5 days and then continued alone for a total of 4-6 weeks. In the case of allergy to penicillin, a combination of cefamandole and an aminoglycoside may be considered in non-anaphylactic allergy. Otherwise, vancomycin is recommended. However, based on in vitro experiments, as well as on small clinical trials, vancomycin is less effective than b-lactams where staphylococci are oxacillin-sensitive, 25 and therefore oxacillin or cloxacillin should be preferred.
The treatment of IE caused by oxacillin-resistant staphylococci requires the use of vancomycin. Teicoplanin may be an alternative, provided that an adequate dosage is given. The goal is to obtain a residual serum concentration of 20-30 mg/l, which is usually obtained with a single daily dose of 10 mg/kg/ day, after an induction phase at 6 mg/kg every 12 hours for 3-4 days. 26 The combination with an aminoglycoside should be reserved for the treatment of IE caused by staphylococci sensitive to aminoglycosides, for no more than 5-7 days.
In non-complicated oxacillin-susceptible native valve endocarditis in IVDUs, a two week course of intravenous cloxacillin, with or without an aminoglycoside, proved to be effective. 25 27 When it is difficult to prolong in-hospital and/or intravenous antibiotic treatment, the combination of oral ciprofloxacin (750 mg twice daily) and rifampicin (300 mg twice daily) after a short period of intravenous treatment is efficacious, 28 29 provided that the strain is susceptible to both drugs and compliance with treatment is high.
Prosthetic valve staphylococcal endocarditis
Such infections are often caused by coagulase-negative staphylococci, which are often resistant to oxacillin. Vancomycin in combination with rifampicin and an aminoglycoside is the most effective combination, provided that rifampicin and the aminoglycoside are active in vitro. If not, an alternative triple association still seems warranted. According to the strain susceptibility, fusidic acid, a fluoroquinolone or fosfomycin may be used. The latter can be used only in the absence of heart failure since it contains a large amount of sodium (1 g of fosfomycin contains 14.4 mmol of sodium and the dose of fosfomycin is 8-12 g/ day).
If the staphylococcal strain is oxacillin-susceptible, the triple combination of oxacillin or vancomycin (in patients allergic to penicillin) plus an aminoglycoside and rifampicin is recommended. The duration of treatment should be six weeks, with at least two weeks of treatment with the aminoglycoside. Valve surgery is most often required.
Antibiotic treatment of IE with negative blood cultures
This is a challenging condition to treat and the diagnostic procedures used should be rigorous, based on close collaboration with the bacteriology laboratory 30 31 (table 4) . In patients with native valve endocarditis, potential causative microorganisms include nutritionally variant streptococci, Gram-negative HACEK coccobacilli, Brucella, and intracellular bacteria that do not grow on conventional media, including Coxiella burnetii, Bartonella, and Tropheryma whipplei. When blood cultures are negative because of prior antibiotic treatment, any other microorganism has to be considered, including staphylococci. While waiting for the results of special blood cultures and serology, treatment should consist of amoxicillin and an aminoglycoside.
Treatment depends on the time elapsed since the implantation of the prosthetic valve. In early-onset IE (onset less than one year after insertion), staphylococci (especially oxacillin-resistant coagulase-negative staphylococci) are most likely to be responsible. A combination of vancomycin, rifampicin, and an aminoglycoside is recommended. Valve replacement should be considered rapidly if the clinical course is unfavourable. In late-onset IE (more than one year after insertion), staphylococci are still potentially responsible but other microorganisms such as streptococci and the HACEK group of bacteria should also be considered. As first line therapy, a combination of vancomycin and an aminoglycoside is recommended. The addition of a third-generation cephalosporin (cefotaxime, 100-200 mg/kg/day in six infusions) is recommended when the first line combination is unsuccessful.
Within ''culture-negative'' endocarditis, some situations deserve special consideration because specific therapeutic regimens are to be used. c Coxiella burnetii is probably the most frequent cause of IE with negative blood cultures, 32 33 although its incidence varies substantially from one geographical area to another. Doxycycline, rifampicin and fluoroquinolones are efficacious in vitro but none of these is bactericidal. The duration of treatment is very long, often several years. Serology appears to be the most reliable criterion of cure, when phase I IgG titres are , 200 and phase I IgA titres are undetectable. Doxycycline is the cornerstone antibiotic, and its efficacy is improved when combined with hydroxychloroquine, which acts as a lysosomotropic alkalinising agent. 34 This combination helps decrease the duration of antibiotic treatment and the failure and relapse rates. c Bartonella, mainly B henselae and B quintana, and occasionally B elizabethae, are second to Coxiella burnetii as agents responsible for culture-negative endocarditis. 33 While B henselae is most commonly encountered in patients with previous valve disease and in subjects who have been in contact with cats, IE caused by B quintana occurs in homeless alcoholics with no previously known heart disease. 35 Treatment consists of a combination of an aminoglycoside and a b-lactam-for example, amoxicillin for at least two weeks. 36 c IE caused by Legionella is rare and occurs mainly in patients with prosthetic valves. The usual treatment regimen consists of a combination of a fluoroquinolone and rifampicin. The duration of treatment should be at least two months, and valve surgery is almost always required.
In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article c Overall, Staphylococcus aureus has become the major pathogen responsible for infective endocarditis c This epidemiological shift results mainly from improved dental care and hygiene and from the growing incidence of nosocomial and healthcare-related endocarditis c Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis should strictly comply with updated experts' guidelines c Short-course (14 days) b-lactam + aminoglycoside treatment is a validated option for uncomplicated penicillinsusceptible native valve endocarditis c A rifampicin-containing triple combination is warranted for the treatment of staphylococcal prosthetic valve endocarditis 
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